drugset / Trial / NCT02990546

Midodrine in the Recovery Phase of Septic Shock

NCT02990546

Phase 3 Withdrawn University of Virginia
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

Timeline

Start
2017-03-01
Primary completion
2018-05-02
Completion
2018-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Midodrine Small molecule 10 mg Oral